Research
Hormonal
Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), restores GLP-1 secretion by rapidly delivering nutrients to the distal gut where L-cells are concentrated, leading to increased satiety and weight loss.
Bariatric surgery, like RYGB, works partly by changing how your gut hormones respond to food. By delivering nutrients to the distal gut faster, it triggers a surge in GLP-1, a hormone that promotes satiety. This hormonal reset is a key factor in the weight loss achieved after surgery.
GoodSupportsHIGH confidence
Potential roles of GLP- 1 in appetite regulation and weight loss are highlighted by a robust increase in secretion in patients after bariatric surgery [49–52]. Although the surge in GLP- 1 release post bariatric procedures, especially Roux- en- Y gastric bypass (RYGB) is thought to be a consequence of rapid nutrient delivery to the distal parts of the gut where the majority of L- cells are located...
Why this rating
Based on multiple cited studies showing increased secretion post-surgery.
Source
The Enteric Neuronal Circuitry: A Key Ignored Player in Nutrient Sensing Along the Gut–Brain Axis
Ester Nikolla et al. · The FASEB Journal · 2025
DOI 10.1096/fj.202500220rr
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The enteric nervous system (ENS) directly senses luminal nutrients (glucose, fatty acids, amino acids) via specific receptors and ion channels on enteric neurons, independent of enteroendocrine cell intermediaries.Good
- GLP-1 release is significantly blunted or absent in morbidly obese individuals and those with type 2 diabetes, contributing to dysregulated nutrient sensing and appetite control.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →